Explore the Potential with AI-Driven Innovation
This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
Our top-notch dedicated system is used to design specialised libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
Q16819
UPID:
MEP1A_HUMAN
Alternative names:
Endopeptidase-2; N-benzoyl-L-tyrosyl-P-amino-benzoic acid hydrolase subunit alpha; PABA peptide hydrolase; PPH alpha
Alternative UPACC:
Q16819; A2RRM4; B0AZP9; B2RCS2; Q8TDC9; Q9H1R1
Background:
Meprin A subunit alpha, also known by its alternative names such as Endopeptidase-2 and PABA peptide hydrolase, plays a crucial role in the proteolytic processing of various substrates. This protein, encoded by the gene with the accession number Q16819, is a component of the meprin family and is involved in the breakdown of extracellular matrix components, which is vital for cellular processes.
Therapeutic significance:
Understanding the role of Meprin A subunit alpha could open doors to potential therapeutic strategies. Its involvement in the proteolytic processing suggests its potential impact on diseases related to extracellular matrix disorders, offering a promising avenue for drug discovery and development.